Back to results
RecruitingPhase 2

Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

NCT06207734

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Charité Berlin

Berlin, Germany

+12 additional locations

Contact

Thomas Decker, Prof.

+49 751 366197Thomas.Decker@onkonet.eu
View on ClinicalTrials.gov
Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer — TrialFind